Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

Phase 4CompletedNCT00832390

Merck Sharp & Dohme LLC29 enrolled

Overview

After 24 weeks of treatment evaluate the efficacy and security.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets

Sex: ALLMin age: 30 YearsMax age: 78 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients Being Treated With Metformin * Patients With Hba1c Between 6.5 % And 12.0%. * Type 2 DM

Change From Baseline in A1C at Week 24

Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.

Time frame: Baseline and 24 Weeks

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.